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REVIEW
PROTON MAGNETIC RESONANCE SPECTROSCOPY
OF THE FRONTAL LOBE IN SCHIZOPHRENICS: A
CRITICAL REVIEW OF THE METHODOLOGY
Rafael Faria Sanches, José Alexandre de Souza Crippa; Jaime Eduardo Cecílio
Hallak; David Araújo; Antonio Waldo Zuardi
SANCHES RF et al. Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the
methodology. Rev. Hosp.Clín. Fac. Med. S. Paulo 59(3):145-152, 2004.
Schizophrenic patients undergoing proton magnetic resonance spectroscopy show alterations in N-acetyl aspartate
levels in several brain regions, indicating neuronal dysfunction. The present review focuses on the main proton magnetic
resonance spectroscopy studies in the frontal lobe of schizophrenics. A MEDLINE search, from 1991 to March 2004, was
carried out using the key-words spectroscopy and schizophrenia and proton and frontal. In addition, articles cited in the
reference list of the studies obtained through MEDLINE were included. As a result, 27 articles were selected. The results were
inconsistent, 19 papers reporting changes in the N-acetyl aspartate levels, while 8 reported no change. Methodological
analysis led to the conclusion that the discrepancy may be due the following factors: (i) number of participants; (ii) variation
in the clinical and demographic characteristics of the groups; (iii) little standardization of the acquisition parameters of
spectroscopy. Overall, studies that fulfill strict methodological criteria show N-acetyl aspartate decrease in the frontal lobe
of male schizophrenics.
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Neuroimaging techniques were in-
troduced in schizophrenia research by
the pioneering work of Jakobi and
Winkler1, showing an enlargement of
the lateral ventricles in chronic schizo-
phrenics. During the last eighty years
there was strong advance in this field,
from the improvement of existing tech-
niques to the introduction of new re-
search capabilities. Among the latter
stands magnetic resonance spectros-
copy (MRS).
MRS is a non-invasive, non-radio-
active procedure that allows quantifi-
cation of several metabolites in spe-
cific regions of the human brain2-5.
Bloch and Purcell originally described
its basic principles in 1946, but it was
only in 1980 that Ackerman and
coworkers developed the in vivo tech-
nique6-7. Since 1991 MRS has been
used to identify chemical changes in
the brain of schizophrenic patients8.
Phosphorus and hydrogen are the
most used atoms in MRS. While phos-
phorus spectroscopy (P31 MRS) makes
possible the research of cell energy
metabolism and neurodevelopment,
hydrogen spectroscopy (better known
as proton spectroscopy, H1 MRS), pro-
vides information about neurotrans-
mitter levels and neuronal integrity, in
addition to measures of energy me-
tabolism9-11.
Among the substances identifiable
by H1 MRS, N-acetyl aspartate (NAA)
- an amino-acid found in neurons - has
been the most investigated compound,
because its concentrations were found
altered in various neuro-psychiatric
pathologies12-14. A decrease in NAA
levels has been associated to neuronal
death, energetic deficit in the cell
body, and axonal injury or lesion15-16.
Studies in schizophrenic patients
using spectroscopy have demonstrated
alterations in NAA levels in some
brain regions, such as the mesial tem-
poral lobe and, to a lesser extent, in the
frontal lobe17-20. Such findings are con-
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sistent with theoretical assumptions
about an abnormal development of
neuronal pathways in these brain re-
gions.
Stanley et al.21 have suggested that
many inconsistencies found in re-
ported results with MRS are due to fast
and complex methodological changes.
Thus, critical methodological analysis
may lead to a better understanding of
these results.
OBJECTIVE
This review aims at discussing
methodological aspects of reported
findings on frontal lobe H1 MRS of
schizophrenic patients.
METHOD
Empirical articles in English were
searched through MEDLINE, between
1991 and March 2004 and only hu-
man studies were included. The key
words were spectroscopy and schizo-
phrenia and proton and frontal. In ad-
dition, articles cited in the reference
list of the studies obtained through
MEDLINE were included. As a result,
27 articles were reviewed.
The studies were divided into two
groups for the analysis of clinical, de-
mographic and procedural variables:
the group of studies showing some
kind of NAA alteration was named G+
and the group not evidencing any al-
teration of NAA levels, even if show-
ing alteration of other metabolites was
called G-. The group means of vari-
ables such as age, sex, use of anti-
psychotics, and echo time were com-
pared.
RESULTS
The data analyzed are summarized
on Table 1 (G+) and Table 2 (G-).
Twenty-six studies included healthy
volunteers as controls, while the re-
maining study used intra-subject com-
parisons. The results of the latter study
showed an increase of the NAA/Cr ra-
tio during anti-psychotic medication,
as compared to a period without medi-
cation22. Among the 26 studies that
have included healthy volunteers as
controls, eight did not evidence a sig-
nificant difference between the groups,
concerning NAA, 13 found NAA de-
crease in patients, as compared to
healthy controls; the remaining five
evidenced NAA changes in subgroups
of patients, only.
The alterations most often found in
the overall comparison of patients with
healthy volunteers were a decrease of
the NAA/Cr ratio17-18, 23-29 and of the
NAA absolute value19, 30,31. Regarding
subgroup comparisons, Heimberg et
al.32, Bustillo et al.33 and Ende et
al.34found NAA differences between
schizophrenics treated with atypical
anti-psychotics as compared to schizo-
phrenics under typical neuroleptics,
and between each subgroup and its
control. Buckley et al.4 evidenced NAA
decrease in male schizophrenics as
compared to normal controls and to fe-
male schizophrenics. Dellamillieure et
al.24 demonstrated NAA decrease in
schizophrenics with deficit syndrome,
as compared to patients without such
deficit and to controls.
Clinical and Demographic
Characteristics
Age
It is important to control age be-
cause there are suggestions showing
that NAA decreases with aging35-36.
Therefore, NAA alterations could be
due to age differences in non-paired
groups. In the studies presently re-
viewed there were no significant dif-
ferences concerning age between pa-
tients and controls, indicating meth-
odological rigor in most of them.
Thomas el al.28, Brooks et al.27 and
Bertolino et al.18 did not find any cor-
relation between age and NAA levels.
Such findings disagree with the results
reported by Omori et al.37, Ende et al.34
and Block et al.38 who observed nega-
tive correlation between age and NAA
in schizophrenic patients.
Ende et al.34, suggest that the nega-
tive correlation between NAA concen-
tration and age may be due to in-
creased partial volume of cerebrospi-
nal fluid (CSF) in the voxel and or to
decreased neuronal density. According
to the same author, a possible expla-
nation for such correlation is the pro-
gressive character of schizophrenia,
leading to cortical atrophy and result-
ing NAA decrease.
When the studies showing NAA al-
teration (G+) were compared with
those not evidencing such alteration
(G-), no significant difference in age
was found (29.87 and 33.54 years of
age, respectively).
Sex
One of the evidences supporting a
possible effect of gender on schizo-
phrenia is given by the study by
Buckley et al.4. In their results, male
schizophrenic patients presented sig-
nificant NAA decrease, as compared to
male controls and to female patients.
Such results are consistent with
neuroimaging findings, in which al-
terations in brain morphology are
more frequent in male than in female
schizophrenics. It has been suggested
that these findings are due to a greater
vulnerability among men to
neurodevelopmental types of schizo-
phrenia39-40.
Fukuzako et al.41 state that a factor
that may have contributed to the lack
of NAA decrease in schizophrenics
shown by their results is the predomi-
nance of females in their sample (11
women and 4 men).
As a conclusion we can say that
though gender cannot be considered a
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Table 1 - Studies of proton spectroscopy in the frontal lobe of schizophrenic patients showing NAA decrease.
Study Subjects N Age Neuro- Site Predomi- VOXEL SV / TE
(M/F) + SD leptics nace (ml) MRSI (Ms)
WM/GM
Bertolino et al. (2001) Without MED SCHZ 23(ND) 36.9 + 8.1 No DLPFR, GM and WM 1.4 MRSI 272
With MED SCHZ 23(18/5) 36.9 + 8.1 Yes (13 ATYP) anterior and
posterior
cingulate
Bertolino et al. (1998) SCHZ 14 (11/3) 16.4 ± 1.7 Yes DLPFR, GM and WM 1.4 MRSI 272
CONT 14 (11/3) 16.1 ± 2.1 anterior and
posterior
cingulate.
Bertolino et al. (1996) SCHZ 10 (8/2) 37.4 ± 8.6 Yes (6 ATYP) DLPFR, GM and WM 1.4 MRSI 272
CONT 10 (ND) 33.1 ± 5.4 anterior and
posterior
cingulate
Block et al. (2000) *SCHZ+EQZA 25(18/7) 35.6 ± 8.3 Yes DLPFR GM and WM 30 SV 272
MIX DIAG 13 (6/7) 45.4 ± 15
CONT FAMILIAL 35(19/16) 49.2 ± 15.4
CONT 19 (7/12) 40.2 ± 5.3
Brooks et al. (1998) SCHZ +SCHZT 16(9/7) 11 ± 1.68 10 with ANTP Frontal pole WM 8 SV 136
CONT 12(6/6) 10.8 ± .72
Buckley et al. (1994) SCHZ + SCHF 20(ND) ND Yes Frontal pole GM and WM 11 SV 68
CONT 15(ND) ND
Bustillo et al. (2001) SCHZ + EQZA 15 (ND) ND Yes DLPFR WM 12.6 SV 30
clozapine
*SCHZ + EQZA 16 (ND) ND Yes
haloperidol
CONT 18 (ND) ND
Bustillo et al. (2002) SCHZ 10 (8/2) 27.2 ± 8.1 Yes Frontal pole WM 12.6 SV 40
CONT 10 (8/2) 26.8 ± 5.9
Callicott et al. (2000) SCHZ 36(30/6) 34 ± 8 (15ATYP, DLPFR, GM and WM 1.4 MRSI 272
CONT 73(45/28) 32.2 ± 8.1 6 without MED) anterior and
posterior
cingulate.
Cecil et al. (1999) SCHZ +SCHF 8 (6/2) 26.4 ± 6.6 No DLPFR WM 8 SV 21
CONT 14 (9/5) 27.7 ± 6.8
Choe et al. (1996) *SCHZ without 55(25/30) 17 – 57 No Frontal pole ND 8 SV 20
SCHZ with med 34(17/17)
CONT 20(10/10) 24-35 Yes
Choe et al. (1994) SCHZ 23(10/13) 17-45 No Frontal pole WM 8 SV 30
CONT 10(5/5) 24-35
Deicken et al. (1997-a) SCHZ 24(21/3) 35.7 ± 12 Yes ND ND 1.3 MRSI 135
CONT 15(11/4) 36.6 ± 6.8
Deicken et al. (1997-b) SCHZ 26 (22/4) 37.3 ± 10.7 (8 ATYP, Anterior GM 1.1 MRSI 135
CONT 16 (12/4) 35.8 ± 7.3 Yes 2 without) cingulate. GM and WM 8 SV 30
Dellamillieure et al. (2000) * DEFICIT- SCHZ 5(ND) ND Yes Anterior
N-DEFICIT SCHZ 17(ND) Yes cingulate.
CONT 21(ND)
Ende et al. (2000) *SCHZ TYP 9 (ND) 36.9 ± 6.4 Yes Anterior GM 2.4 MRSI 135
SCHZ ATYP 10(ND) 32.5 ± 11 Yes cingulate.
CONT 16 (11/5) 34.9 ± 13.6
Hagino et al. (2002) SCHZ 13(11/2) 23.7 ± 5 Yes DLPFR GM and WM 6 SV 270
CONT 13(11/2) 20.9 ± 2.3
Heimberg et al. (1998) SCHZ + SCHZA 13(13/0) ND Yes Frontal pole GM 8 SV 30
CONT 14(ND) ND (2ATYP)
Thomas et al. (1998) CHILD-SCHZ 12(ND) ND Yes (10) Anterior GM 8 SV 20
CONT 12 (6/6) 11 ± 3 cingulate.
SCHZ=schizophrenics; CONT=healthy controls; SCHF=schizophreniforms; SCHZT=schizotypicals; SCHZA=schizoaffectives; CHILD-
SCHZ=childhood-onset schizophrenia; MIX DIAG=mixed psychiatric diagnoses; ±SD=standard deviation; SV= single voxel. MRSI=functional
spectroscopy. TE=echo time; DLPFR=dorsolateral prefrontal region; WM=white matter; GM=gray matter. ND=not described. *=NAA statistical
difference as compared to control group. ANTP=anti-psychotics. ATYP=atypical anti-psychotics. TYP=typical anti-psychotics. MED=medication
determinant factor in the results pre-
sented, it seems that male schizophren-
ics are more likely to present decrease
in the NAA levels.
Medication
The strongest evidence of NAA de-
crease is found in chronic schizo-
phrenic patients. One reason, already
discussed, is the possible negative cor-
relation between NAA and age. An-
other possibility is that chronic pa-
tients generally have a history of pro-
longed use of anti-psychotics, al-
though the consequences of such treat-
ment on neuronal functioning are un-
known. Some studies have concen-
trated on that variable, such the men-
tioned intra-subject study by
Bertolino et al.22, which found a NAA/
Cr increase in medicated schizophrenic
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patients. Nevertheless, several limita-
tions were pointed out in this study by
Bustillo et al.33: it is a naturalistic,
non-controlled study; used NAA/Cr
ratio, and the NAA change observed
was only 9%, which can be seen as a
normal variation, although reaching
statistical significance in the dorsola-
teral pre-frontal cortex (DLPFC). In
their own results, Bustillo et al.33 re-
ported NAA decrease in schizophren-
ics treated with haloperidol, as com-
pared to controls and patients taking
clozapine, raising the hypothesis of an
association of typical anti-psychotics
with neuronal toxicity.
Two other studies have analyzed if
the type of anti-psychotic drug may
interfere with the NAA levels. Omori
et al.37 did not find any differences in
the frontal lobe, when they compared
typical anti-psychotic drugs (n=13) to
atypical ones (n=5). In contrast,
Heimberg et al.32 reported NAA/Cr in-
crease in patients taking atypical anti-
psychotic drugs (n=2), as compared to
schizophrenics taking typical
neuroleptics (n=4). Nevertheless, the
last result should be seen with caution,
due to the small number of subjects
participating in the study.
Still about the effects of anti-psy-
chotic drugs on NAA, this review
found five well-designed studies. Three
of them used schizophrenic patients
under no medication and, two of the
studies were longitudinal. Cecil et al.25
and Choe et al.17 studied non-medi-
cated patients and found NAA/Cr de-
crease. However, Bartha et al.42 did not
find any NAA alteration in non-medi-
cated schizophrenics. In a longitudinal
follow-up study, Choe et al.29 observed
that schizophrenic patients (n=55) had
decreased levels of NAA/Cr, even
though such levels did not change
with anti-psychotic drugs during a
treatment period of up to six-months
(n=34). The comparison of this study
with the other longitudinal investiga-
tion reviewed (Bertolino et al.22) is
questionable, because of critical meth-
odological differences. In another lon-
gitudinal study, Bustillo et al.31 found
NAA decrease during the second scan
(after the use of anti-psychotic drugs).
It is noteworthy that five stud-
ies4,24,27,34,43 have reported no signifi-
cant differences in NAA levels be-
tween subgroups of non-medicated
and medicated patients. Accordingly,
the results obtained by Callicott et
al.23, Bertolino et al.18,26, Deicken et al.
19,30 and Fukuzako et al.41 did not show
any correlation between NAA concen-
tration and dosage of anti-psychotic
drug.
Because of the difficulty in per-
forming experiments with non-medi-
cated schizophrenic patients and the
diversity of results found, the query
about the real interference of medica-
tion on the NAA levels is still to be
answered.
Experimental Design
Sample Size
Studies in schizophrenic patients
using spectroscopy are generally car-
ried out with a small number of pa-
tients. There are several reasons for
that, from the difficulty of recruiting
patients and the high costs of the pro-
cedure to the time spent in each exami-
nation. Because of that, a question
raised about such studies is whether
Table 2 - Studies of frontal lobe proton spectroscopy in schizophrenic patients who did not show NAA decrease.
Study Subjects N Age Neuro- Site Predomi- VOXEL SV / TE
(M/F) + SD leptics nace (ml) MRSI (Ms)
WM/GM
Bartha et al. (1997) SCHZ 10 (8/2) 26.3 ± 6.4 No Cingulate GM 4.5 SV 20
CONT 10 (8/2) 24.4 ± 5.1
Bertolino et al. (2000 SCHZ 8(ND) 40.1 ± 8.7 No DLPFR GM 1.4 MRSI 272
CONT 7 (5/2) 36.4 ± 7.3
Callicott et al. (1998) SCHZ + SCHZA 47 (43/4) 34.2 ± 8.8 8 without DLPFR, GM and
CONT 66 (42/24) 32.9 ± 8.2 anterior WM 1.4 MRSI 272
and posterior
cingulate
Fukuzako et al. (1995) SCHZ 15(4/11) 39.3 ± 7.6 Yes Frontal pole. ND 27 SV 135
CONT 15(4/11) 38.8 ± 7.8
Omori et al. (2000) SCHZ 20 (12/8) 23–43 Yes Frontal pole. WM 8 SV 136
CONT 16 (10/6) (5 ATYP,
2 without)
Sigmundsson et al. (2003) SCHZ 25 (24/1) 34.9 ± 8 Yes DLPFR. WM 2 SV 136
CONT 26 (22/4) 31.8 ± 6.7
Stanley et al. (1996) SCHZ 13(11/2) 26 ± 7 No DLPFR. WM (70%) 8 SV 20
SCHZ 12(10/2) 26 ± 7 Yes acute GM (30%)
SCHZ 12(11/1) 41 ± 5 Yes chronic
CONT 24(24/0) 32 ± 11
Steel et al. (2001) SCHZ 10 (5/5) 34 ± 14 Yes Frontal pole. WM 15 SV 145
CONT 10 (4/6) 35 ± 7
SCHZ=schizophrenics; CONT=healthy controls; SCHZA=schizoaffectives; ±SD=standard deviation; SV= single voxel. MRSI=functional
spectroscopy. TE=echo time; DLPFC=dorsolateral prefrontal cortex; DLPFR=dorsolateral prefrontal region; WM=white matter; GM=gray
matter. ATYP=atypical anti-psychotics.
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the number of subjects used is enough
to minimize type II errors44. Steel et
al.45 and Bertolino et al.46 admit that
the lack of significant NAA decrease
observed in their studies may be due
to the small number of subjects used,
10 and 8 respectively.
Considering the difficulties in per-
forming such kind of study in large
number of subjects, the ones, which
achieve bigger samples, should be ap-
preciated.
Voxel Size and Location
Even though spectroscopy has
many advantages, there are some short-
comings to be surmounted, such as for
example, its low anatomical defini-
tion. By using the 1.5 Tesla magnetic
field, H1 MRS gets a good resolution,
with voxels measuring from one to
eight ml. When compared to P31 MRS,
H1 MRS allows the selection of smaller
voxels, because proton sensitivity is
fifteen times larger than that of phos-
phorus. As far as the intensity of mag-
netic fields can be increased, voxels
with still smaller volumes would be
selected. The advantage of small
voxels is the decrease of the partial
volume effect, such as the ratio of
white/gray matter or CSF. On the other
hand, smaller voxels decrease the sig-
nal-to-noise ratio and thus, the spec-
trum quality is lowered43.
A pertinent query is whether NAA
changes observed in some studies are
due to decrease of the volume of the
structure, with resulting presence of
CSF, white matter (WM) or gray (GM)
from neighboring structures. Several
authors 4,22,32,41-42,45 raise the possibility
of the influence of results by adjacent
areas. Stanley et al.43 for instance, ad-
mit that the lack of change in
metabolites shown by their results may
be explained by the fact that 70% of
the voxel was composed by WM, bear-
ing in mind that the differences in
metabolites only can be found in the
GM.
Among the articles reviewed, there
was a considerable variation in size
among the voxels selected, ranging
from 1.1 ml to 30 ml.
In addition, there was large varia-
tion in the localization of voxels, even
though they were all inside the frontal
lobe. Table 3 shows the distribution of
studies by voxel localization in the
frontal lobe (dorsolateral prefrontal re-
gion, frontal pole, cingulate). In the re-
viewed studies, NAA decrease was
found in the three sub-regions, as
pointed out before18.Taking into con-
sideration that NAA changes are not
limited to a specific region, it is even
more necessary to be able to decrease
voxel size without impairing the signal-
to-noise ratio. Moreover, with the devel-
opment of techniques for separating
WM from GM and to minimize CSF in-
terference in the voxel, more reliable
results will certainly be obtained.
Laterality
Some spectroscopy studies re-
viewed in this article (N=11) did not
evaluate the frontal region bilaterally.
Among 1618-19,22-26,28-30,34,44-48 articles
that have evaluated bilateral frontal
lobe, in ten18-19,22-26,28-29,34 the abnor-
malities were the same bilaterally and
in two30,47 studies NAA differences
were found only on the left side. In the
other four44-46,48 studies no differences
were found. When only one side was
selected, the left frontal lobe was
clearly preferred for investigation (N=
104,27,31-33,37-38,41-43) as compared to the
right frontal lobe (N=117). There were
NAA abnormalities in 184,18-19,22-34,38,47
(69%) out of 26 articles that evaluated
the left side, whereas NAA differences
occurred in 1117-19,22-26,28-29,34 (64%) out
of 17 articles that studied the right
side. Therefore, these results suggest
that the NAA abnormalities in the fron-
tal lobe are not influenced by brain
laterality.
MRS Parameters
The variation of acquisition pa-
rameters in spectroscopy, as well as the
physicochemical proprieties of the
measured substances may distort the
results obtained. Several authors30,41,43
admit the possibility of interference of
the relaxation times T1 and T2 in their
results. T1 is the time the atom nucleus
takes to return to its low energy basal
state, which is more stable, while T2,
transversal relaxation time, is the time
the nucleus takes to become out of
phase (such as clocks from several
countries, winding in the same fre-
quency, but showing different times).
Times T1 and T2 are determined by the
molecular environment around the
atom nucleus.
Table 3 - Distribution of proton spectroscopy studies in schizophrenic patients
paired with healthy controls among the frontal lobe sub-regions.
Frontal pole Cingulate DLPFR
*Brooks et al. 1998 *Dellamillieure et al. 2000 *Bustillo et al. 2001
*Buckley et al. 1994 *Deicken et al. 1997-b *Bertolino et al. 2001
*Bustillo et al. 2002 *Ende et al. 2000 *Block et al. 2000
*Choe et al. 1994 *Thomas et al. 1998 *Bertolino et al. 1998
*Choe et al. 1996 Bartha et al. 1997 *Bertolino et al.1996
*Heimberg et al 1998 Bertolino et al. 2001 *Callicott et al. 2000
Fukuzako et al. 1995 Bertolino et al. 1998 *Cecil et al. 1999
Omori et al. 2000 Bertolino et al. 1996 *Hagino et al. 2002
Steel et al. 2001 Callicott et al. 2000 Bertolino et al. 2000
Callicott et al. 1998
Sigmundsson et al. 2003
Stanley et al. 1996
DLPFR =dorsolateral prefrontal region; *indicates change in NAA concentration.
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Other parameters previously de-
fined by the authors, such as: Echo
Time (TE – the time between the 90
degree pulse and the maximum in the
echo in a spin-echo sequence), use or
not of metabolite ratio, and predomi-
nance of white or gray matter made it
difficult the comparison of the results
obtained.
The definition of TE depends on
the metabolite of interest and so, a
short TE is preferable when the focus
is in substances such as glutamate.
However, if NAA is the center of atten-
tion, the NAA peak definition im-
proves with a longer TE.
Block et al.38 found NAA/Cho de-
crease in schizophrenics, only when
they used 272 ms TE. With 30 ms there
was no difference, probably due to
higher standard deviations. Fukuzako
et al.41 reported that the NAA/Cr ratio
decreases when TE drops from 135 ms
to 50 ms.
It can be seen that nine4,17,24-25,28-
29,31-33
 of the 19 studies that found
NAA decrease used a short TE, indi-
cating that TE is not the only deter-
minant of the results obtained.
The best way to determine the
brain concentration of a substance is
its absolute value, but as such meas-
urement is highly complex, the results
are not always reliable. The determi-
nation of NAA ratio with other sub-
stances (NAA/Cr, NAA/Cr+Cho, NAA/
Cho) is, on the other hand, easily ob-
tainable, does not vary with the re-
laxation times T1 and T2, and is not
affected by CSF influence. The disad-
vantage is that the result is a function
of both the denominator and the nu-
merator.
Even when the quantification in
absolute value is used, the technique
employed in this situation, also uses a
kind of “ratio”. For instance, in
Heimberg et al.’s32 study, the water con-
centration was used as a reference for
the quantification of metabolites of in-
terest, assuming that the magnetic
characteristics of the water do not
change in pathological situations.
As many as 1717-18,22-29,32,37-38,41,44,46-
47 from the 27 articles reviewed, used
“ratio” instead of absolute values.
Among them, 1317-18,22-29,32,38,47 studies
found decrease in the NAA ratio. From
the eight studies that did not find NAA
changes, two42-43 have been criticized
by Bertolino and Weinberger20. They
argued that the use of absolute values
based on previous knowledge of
metabolite concentration is unreliable,
because measurements obtained in dif-
ferent sessions are hard to replicate.
CONCLUSION
The main difficulty in analyzing
these 27 articles resulted from the great
variation in the methodological vari-
ables discussed above. None of those
aspects, by themselves, was able to
predict the results obtained in the stud-
ies.
Though the studies were rigorous
in many ways, few reached satisfactory
criteria, both in respect to the clinical
and demographic characteristics, and
in the parameters of image acquisition.
Small subject group sizes, samples
with a high proportion of female
schizophrenics, large voxel volume
and short TE are factors likely to im-
pair the detection of NAA change. Tak-
ing into account the number of pa-
tients studied (> 20), the predominance
of male patients (>80%), the TE (> 135
ms), the voxel size (< 2 ml), six well
designed studies can be selected. Four
out of these six best-designed stud-
ies19,22-23,30 showed a decrease in the
NAA levels in the frontal lobe of
schizophrenics; and two44,48 reported
negative findings.
Thus, the results of the present re-
view show that it is not clear if there
is an association between NAA abnor-
malities in the frontal lobe and schizo-
phrenia. Since many aspects of this
disorder are heterogeneous, standardi-
zation of spectroscopic methodology
and a more judicious selection of sub-
jects are likely to generate more reli-
able evidence concerning the role of
NAA in schizophrenia.
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RESUMO
SANCHES RF e col. Espectroscopia de
Próton por ressonância magnética
de lobo frontal em esquizofrênicos
– Revisão crítica da metodologia.
Rev. Hosp. Fac. Med.S. Paulo
59(3):145-152, 2004
Pacientes esquizofrênicos submeti-
dos à espectroscopia de próton por res-
sonância magnética demonstram alte-
rações nos níveis de N-acetilaspartato
em diversas regiões cerebrais, supor-
tando a hipótese de disfunção neuro-
nal nestas áreas. Objetiva-se apresen-
tar uma revisão da literatura, sobre os
principais estudos de espectroscopia
de próton por ressonância magnética
na região frontal em esquizofrênicos.
Utilizou-se o indexador MEDLINE, no
3192.p65 13/07/04, 15:20150
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período entre 1991 e março de 2004,
com o cruzamento dos termos spec-
troscopy, schizophrenia, proton e fron-
tal. Foram selecionados 27 artigos ori-
ginais, cujos resultados mostram-se
discordantes quanto à alteração nos
valores de N-acetilaspartato (19 artigos
apresentaram alterações nos níveis de
N-acetilaspartato e oito estudos não
apresentam alterações). A presente re-
visão sugere que esta diversidade de
resultados pode ser atribuída aos se-
guintes fatores: 1-número de partici-
pantes; 2- variação nas características
clínicas e demográficas dos grupos; 3-
pouca padronização dos parâmetros de
aquisição dos espectros. Os artigos que
satisfazem os critérios metodológicos
mais rígidos sugerem diminuição de
NAA no lobo frontal de esquizo-
frênicos do sexo masculino.
UNITERMOS: Espectroscopia.
Próton. Frontal. Esquizofrenia. Revi-
são.
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